Paul Biondi, MBA
What if we could change how drugs are developed?
The pharmaceutical industry uses a legacy point-to-point sub-optimized approach to drug discovery and development that is inefficient, expensive, and too often ends in failure.
Valo has pioneered a new approach to target discovery and drug development—one that is based on human-centric data and machine learning at every step.
Valo is a mission-driven technology company that was created with the belief that the drug discovery and development process can and should be better—faster, less expensive, and with a higher probability of success.
Founded by Flagship Pioneering, Valo is using human-centric data and machine learning computation to transform the drug discovery and development process. As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate.
Valo's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.
Meet our team of preeminent leaders in science, technology, pharmaceuticals, and public policy, united to change the world.